Condition: Esophagogastric Junction Adenocarcinoma · Gastric Adenocarcinoma · Esophageal Adenocarcinoma · Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
With this trial, we aim to evaluate a new combination therapy with tislelizumab and FLOT chemotherapy before surgery (neoadjuvant) for locally advanced, resectable adenocarcinoma of the esophagus or stomach (EGA). The aim of this phase Ib trial is to determine whether this combination is safe and clinically active enough to support the continuation of this concept in subsequent trials investigating novel drug combinations in the neoadjuvant setting of locally advanced EGA. As many patients are unable to tolerate the postoperative part of the standard therapy concept, we aim here to assess a prolongation of preoperative therapy to 6 or 8 applications of FLOT, instead of the routinely administered 4 pre- and 4 postoperative applications, in combination with tislelizumab.
This description comes directly from the study's public registry record.
Florian Lordick, Prof. Dr. · +49 341 97 12560 · Florian.lordick@medizin.uni-leipzig.de
Claudia Pauligk, Dr. · +49 (0) 69 / 5899 787 - 52 · neotislega@ikf-khnw.de
Always discuss trial participation with your own doctor first.
| Krankenhaus Nordwest GmbH Institut für Klinisch-Onkologische Forschung (IKF) | Frankfurt, Germany | Recruiting |
| Hämatologisch-Onkologische Praxis Eppendorf (hope) | Hamburg, Germany | Not Yet Recruiting |
| Universitätsklinikum Leipzig | Leipzig, Germany | Not Yet Recruiting |
| Klinikum rechts der Isar München der TU München | München, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07059299